New drug combination for PIK3CA-mutated breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new combination of two drugs (JS105 plus dalpiciclib and fulvestrant) against a standard combination (dalpiciclib plus fulvestrant) for people whose breast cancer has a PIK3CA mutation. The goal is to see if adding JS105 helps control the cancer longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your breast cancer is HR-positive, HER2-negative, and has spread or come back after treatment.
- Your tumor has a specific gene change called PIK3CA mutation.
- You have not been treated with fulvestrant or certain targeted cancer drugs before.
- You are in good overall health (able to care for yourself, with no major uncontrolled health problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill (JYP0035) combined with fulvestrant, a standard hormone therapy, for advanced breast cancer that has a specific gene change called PIK3CA. The goal is to see if the combination helps control the cancer better than fulvestrant alone.
This trial tests whether a newer drug called dalpiciclib works better than chemotherapy when combined with two other anti-HER2 drugs (pyrotinib and trastuzumab) for advanced breast cancer that has spread. The goal is to find a treatment that works well with fewer side effects.
This study tests whether combining two drugs (dalpiciclib and SHR-A1811) before surgery can shrink early-stage breast cancers that are hormone-sensitive and HER2-low. The goal is to see if this approach improves outcomes for patients with intermediate-to-high risk disease.
This trial tests a combination of medications (inavolisib, pertuzumab, trastuzumab, and nab-paclitaxel) given before surgery to shrink tumors in people with HER2-positive early breast cancer that also has a specific gene change (PIK3CA mutation). The goal is to see if this treatment is effective and safe.
This trial is testing a drug called Inavolisib (a type of targeted therapy) given before surgery for people with early-stage, hormone receptor-positive, HER2-negative breast cancer that has a specific genetic change (PIK3CA mutation). The goal is to see if adding Inavolisib to standard endocrine therapy can shrink the tumor more effectively.
This trial tests two different combinations of medicines for people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a specific gene change called PIK3CA. The goal is to see which combination is better at slowing down the cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.